July 25, 2024
EU Panel Recommends Wegovy for Preventing Cardiac Events, Following FDA Lead
Wegovy, EU panel, FDA, cardiac events, weight loss, Novo Nordisk
US Government Inks $113 Million Deal with Siga to Enhance Smallpox and Mpox Reserves
US government, Siga, smallpox, mpox, Tpoxx, procurement deal, public health
Pfizer Expands API Manufacturing Site in Singapore with $740M+ Investment
Pfizer, API manufacturing, Singapore, facility extension, investment
Ipsen Secures Ex-US Rights to Day One’s Pediatric Cancer Medication with $111M Upfront Investment
Ipsen, Day One, Pediatric Cancer, Tovorafenib, Ex-US Rights, $111M Upfront Investment
BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease
BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms
Sanofi Deprioritizes Four Assets, Including Mid-Stage Dwarfism Treatment
Sanofi, dwarfism, mid-stage treatment, asset deprioritization, rare disease, achondroplasia
Viking Therapeutics Accelerates Obesity Drug Development to Phase 3 Trials
Viking Therapeutics, Obesity Drug, Phase 3 Trials, GLP-1/GIP Receptor Agonist, VK2735, Weight Loss, Market Competition
Biogen and Sage Therapeutics Discontinue Development of SAGE-324 for Essential Tremor Following Mid-Stage Trial Failure
Biogen, Sage Therapeutics, SAGE-324, Essential Tremor, Mid-Stage Trial, Neurological Disorder, GABA Receptor Modulator, Clinical Development
Novartis Partners with Dren Bio in $3 Billion Deal for Targeted Myeloid Engagers
Novartis, Dren Bio, Myeloid Engagers, Biotech, Pharmaceutical, Alliance, $3 Billion Deal
Sanofi’s Dupixent Sales Surpass €3 Billion for the First Time
Sanofi, Dupixent, quarterly sales, record high, asthma medicine, earnings forecast